Innolith makes breakthrough in vehicle batteries
Energy company Innolith has developed a new type of battery that gives electric vehicles a range of 1,000km. The innovation has now been registered for a patent and will be launched on the market via an initial pilot production.
Basel energy company Innolith has developed a battery innovation at its German laboratory in Bruchsal. According to a press release, this rechargeable battery is capable of powering an electric vehicle for over 1,000km on a single charge. The battery avoids exotic and expensive materials and therefore radically reduces overall cost.
In addition to its range and cost advantages, the new battery is also safer. It is the first non-flammable lithium-based battery for use in electric vehicles. Rather than conventional flammable organic electrolytes, the Innolith battery uses a non-flammable inorganic electrolyte.
A patent application has been filed for this battery technology and Innolith is maintaining commercial confidentiality on the cell chemistry mechanism. The chemistry used in this battery has reportedly been proven to operate for more than 55,000 full depth discharge cycles, which is between 10 and 100 times the maximum number of cycles of existing lithium ion batteries in use today.
Innolith will be bringing its Energy Battery to market via an initial pilot production in Germany soon. The aim is to later conclude licensing partnerships with battery manufacturers. BaselArea.swiss supported Innolith in 2018 with the opening of the global headquarters in Basel.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More